The stock of AIkido Pharma Inc. (NASDAQ:AIKI) increased by remained unchanged at $0.86, up 2.18 percent. The last five days have seen an average of 4,595,240 shares of common stock traded. 5 times new highs were reached in the current year, with a fall of -$0.0173. The average number of shares traded over the last 20 days was 9,571,720, while the average volume over the last 50 days totaled 4,612,274.
AIKI stock appreciated 9.35% since last month. On 09/23/21, the company’s shares reached a one-month low of $0.7312. The stock touched a high of $2.55 on 02/16/21, after rallying from a low of $0.47 in 52 weeks. The price of AIKI stock has declined by -1.98% or -$0.0173 this year, reaching a new high 5 times. Still, the stock price is down -66.42% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
There have been 175 days since AIkido Pharma Inc. (AIKI) last reported insider trading activity on May 03. On May 03, CEO Hayes Anthony acquired 10,000 shares at $0.99 each. This transaction resulted in the insider spending $9,900. On Apr 29, Hayes Anthony added 10,000 shares at a price of US$0.99. After the transaction, the insider now owns 68,430 shares. CEO Hayes Anthony had earlier bought 10,000 shares on Apr 22 for $0.93 a share. The transaction was completed for $9,300.
The PE ratio of AIkido Pharma Inc. has varied between 4.554 and 0.0635 in the last five years. Beta for the stock is 1.41.
For the recent quarter, AIkido Pharma Inc.’s quick ratio was 97.00, while its current ratio was 97.00, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $6.55 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. AIKI’s return on assets (ROA) during the last 12 months has been -10.40%. In the meantime, the return on equity (ROE) for the last 12 months was -10.50%. ROE has averaged -68.79 in the past year for the broader industry.
Here’s a quick look at AIkido Pharma Inc.’s (AIKI) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 54.83%, suggesting the stock is Neutral, with a 33.94% historical volatility rate.
The stochastic %K and %D were 40.27% and 39.85% respectively, while the average true range (ATR) was 0.0582. Based on the 14-day stochastic reading of 42.61%, the RSI (14) reading is 54.63%. On the 9-day MACD Oscillator, the stock is at -0.0028.
Analysts have assigned AIkido Pharma Inc. (AIKI) an Buy rating. AIKI is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is AIKI’s price target for the next 12 months?
The current consensus forecast for the stock is between $2.00 and $2.00, with a median target price of $2.00. In analyzing these forecasts, the average price target given by analysts for AIkido Pharma Inc. (AIKI) is $2.00.